Synthesis and pharmacological evaluation of (Z)-9(heteroarylmethylene)-7-azatricyclo[4.3.1.03,7]decanes:: Thiophene analogues as potent norepinephrine transporter inhibitors

被引:14
作者
Zhou, J
Kläss, T
Zhang, A
Johnson, KM
Wang, CZ
Ye, YP
Kozikowski, AP
机构
[1] Georgetown Univ, Med Ctr, Dept Neurol, Drug Discovery Program, Washington, DC 20057 USA
[2] Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA
关键词
D O I
10.1016/S0960-894X(03)00786-8
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To further explore the structure-activity relationships (SARs) of certain tropanes, and to gain insights into the structural features required for high activity and selectivity at norepinephrine transporters (NET), we have introduced both five- and six-membered heteroaromatic moieties such as substituted pyridyl, pyrazinyl, pyrimidyl, thiazolyl, and mono- or disubstituted thienyl groups into conformationally constrained, tricyclic tropane analogues. A number of (Z)-9-(heteroarylmethylene)-7-azatricyclo[4.3. 1.0(3,7)]decanes were synthesized, and their abilities to block dopamine, serotonin, and norepinephrine reuptake by their respective transporters were evaluated. It was found that the five- or six-membered N-containing aromatics are too basic to display high NET activity, while some of the thiophene analogues were identified as potent and selective NET inhibitors. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3565 / 3569
页数:5
相关论文
共 33 条
[1]   Neurotransmitter transporters as molecular targets for addictive drugs [J].
Amara, SG ;
Sonders, MS .
DRUG AND ALCOHOL DEPENDENCE, 1998, 51 (1-2) :87-96
[2]  
Barker Eric L., 1995, P321
[3]   Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder [J].
Biederman, J ;
Spencer, T .
BIOLOGICAL PSYCHIATRY, 1999, 46 (09) :1234-1242
[4]  
Blier P, 2001, J PSYCHIATR NEUROSCI, V26, pS1
[5]   Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in Attention Deficit/Hyperactivity Disorder [J].
Bymaster, FP ;
Katner, JS ;
Nelson, DL ;
Hemrick-Luecke, SK ;
Threlkeld, PG ;
Heiligenstein, JH ;
Morin, SM ;
Gehlert, DR ;
Perry, KW .
NEUROPSYCHOPHARMACOLOGY, 2002, 27 (05) :699-711
[6]  
Bymaster FP, 2002, EUR NEUROPSYCHOPHARM, V12, pS418
[7]   Pharmacotherapies for treatment of cocaine abuse: Preclinical aspects [J].
Carroll, FI ;
Howell, LL ;
Kuhar, MJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (15) :2721-2736
[8]   Animal models of attention-deficit hyperactivity disorder [J].
Davids, E ;
Zhang, KH ;
Tarazi, FI ;
Baldessarini, RJ .
BRAIN RESEARCH REVIEWS, 2003, 42 (01) :1-21
[9]  
DONDONI A, 1986, SYNTHESIS-STUTTGART, P757
[10]   Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression [J].
Fleishaker, JC .
CLINICAL PHARMACOKINETICS, 2000, 39 (06) :413-427